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Evidence for Polygenic Susceptibility
to Multiple Sclerosis—The Shape of Things to Come
The International Multiple Sclerosis Genetics Consortium (IMSGC)1,*
It is well established that the risk of developing multiple sclerosis is substantially increased in the relatives of affected individuals and
that most of this increase is genetically determined. The observed pattern of familial recurrence risk has long suggested that multiple
variants are involved, but it has proven difﬁcult to identify individual risk variants and little has been established about the genetic
architecture underlying susceptibility. By using data from two independent genome-wide association studies (GWAS), we demonstrate
that a substantial proportion of the thousands of variants that individually fail to show statistically signiﬁcant evidence of association
have allele frequencies in cases that are skewed away from the null distribution through the effects of multiple as-yet-unidentiﬁed risk
loci. The collective effect of 12,627 SNPs with Cochran-Mantel-Haenszel test (p< 0.2) in our discovery GWAS set optimally explains ~3%
of the variance in MS risk in our independent target GWAS set, estimated by Nagelkerke’s pseudo-R2. This model has a highly signiﬁcant
ﬁt (p ¼ 9.90E-19). These results statistically demonstrate a polygenic component to MS susceptibility and suggest that the risk alleles
identiﬁed to date represent just the tip of an iceberg of risk variants likely to include hundreds of modest effects and possibly thousands
of very small effects.Multiple sclerosis (MS [MIM 126200]) is a complex demy-
elinating disorder of the central nervous system. The
etiology of the disease is not well understood but epidemi-
ological studies provide undeniable evidence that genetic
factors are involved.1–4 Despite these extensive data, there
was little progress identifying relevant genes prior to the
emergence of genome-wide association studies (GWAS).
For more than 30 years the only known MS genetic risk
locus was the major histocompatibility complex (MHC)
on chromosome 6p21.5,6 All this changed in 2007 when
the International Multiple Sclerosis Genetics Consortium
(IMSGC) completed the ﬁrst MS GWAS7 and identiﬁed
one new susceptibility locus, IL2RA (MIM 147730), and
simultaneously with two other reports conﬁrmed another
susceptibility locus, IL7R (MIM 146661).8,9 Since then
progress has been rapid and the list of established MS risk
loci has grown considerably (see Table 1). To date all of
the newly identiﬁed MS risk alleles are common, exert
only modest individual effects on risk (odds ratios 1.1–
1.3), and ostensibly act independently. Even in combina-
tion with the much more substantial effects attributable
to the MHC, these known MS risk loci account for less
than half of the familial clustering observed epidemiologi-
cally. It is inescapable that other genetic risk factors exist
and that much remains to be discovered about the genetics
of MS. To aid in this discovery process, it would be helpful
to estimate the form of this as-yet-undiscovered genetically
determined risk.
GWAS, which by design examine common variation,
have naturally driven the identiﬁcation of common risk
alleles for MS rather than rare variants. At the same time,
the virtual absence of large extendedMS families10 coupled
with the total absence of any consistent evidence for
linkage outside theMHC region11 indicates that rare alleles1For a list of contributing members of the consortium, see the Acknowledgme
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The Amexerting very large effects are unlikely to play a prominent
role in the genetics of MS. The relationship between
familial recurrence risk and the degree of relatedness
provides some guidance to the underlying genetic architec-
ture of MS12–14 and several studies have demonstrated that
this relationship is distinctly nonlinear, suggesting that
susceptibility is probably determined by multiple risk
alleles, each exerting modest individual effects.1–4,15,16
Unfortunately, this type of segregation analysis is insensi-
tive to the number of involved loci and is largely unable
to distinguish between dozens of modest effects, hundreds
of weak effects, or thousands of very weak effects.15 In line
with the polygenic model proposed by Fisher,17 it is logical
to anticipate that the genetic architecture underlying
susceptibility to MS will involve a wide spectrum of risk
allele frequencies and effect sizes.13 Under such a polygenic
model, we would expect that many of the SNPs tested in a
GWAS will be genuinely associated with disease, although
most to only a minor degree. In this context we should
see a systematic inﬂation of association scores across the
genome, the pattern of which would be a reﬂection of
the linkage disequilibrium (LD) between tested variants
and the underlying risk alleles. The genome-wide inﬂation
of association scores, beyond that which would be ex-
pected through sampling variance alone, is a well-recog-
nized aspect of GWAS; however, most of this phenomenon
is known to stem from subtle experimental biases, such as
hidden population stratiﬁcation and differential missing-
ness.13 In a recently published ground-breaking study,
the International Schizophrenia Consortium (ISC)18
conﬁrmed the existence of polygenic inﬂuences in schizo-
phrenia (MIM 181500) by showing that a small fraction
of the variance in disease status (~3%) was signiﬁcantly
associated with a score based on multiple SNPs, none ofnts
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Table 1. Established Non-MHC MS Risk Alleles
Susceptibility
Gene
RS
Number
OR
Estimate Allele Reference
IL7RA rs6897932 1.18 C Gregory et al., 2007;8
IMSGC, 2007;7
Lundmark et al.,
20079
IL2RA rs12722489 1.25 C IMSGC, 20077
IL2RA rs2104286 1.19 T IMSGC, 200825
CLEC16A rs6498169 1.14 G IMSGC, 20077
CLEC16A rs12708716 1.19 A IMSGC, 200926
CD58 rs12044852 1.24 C IMSGC, 20077
CD58 rs2300747 0.77 G De Jager et al., 200819
CD226 rs763361 1.12 A IMSGC, 200926
TYK2 rs34536443 1.32 G Ban et al., 200927
CD6 rs17824933 1.18 G De Jager et al., 200819
IRF8 rs17445836 0.8 A De Jager et al., 200819
TNFRSF1A rs1800693 1.2 C De Jager et al., 200819
TNFRSF1A rs4149584 1.58 T De Jager et al., 200819
METTL1 rs703842 0.81 G ANZgene, 200928
METTL1 rs10876994 0.82 C ANZgene, 200928
METTL1 rs12368653 1.15 A ANZgene, 200928
CD40 rs6074022 1.22 G ANZgene, 200928
CD40 rs1569723 1.22 C ANZgene, 200928which were signiﬁcantly associated with the disease at a
genome-wide level in their own right. In short, they
showed that despite sampling variance and the confound-
ing inﬂuences of population stratiﬁcation and differential
missingness, the systematic inﬂuences of polygenic effects
can be demonstrated. The ISC further demonstrated that
the extent of variance explained increased as they incorpo-
rated additional SNPs with less signiﬁcant p values into
their scoring. With simulations they showed that this
pattern most probably indicated that polygenic risk in
schizophrenia is determined by modest numbers of larger
effects and increasing numbers of smaller effects.18
Two previously published MS GWAS data sets were
employed in this analysis. Data from the International
Multiple Sclerosis Genetics Consortium (IMSGC) GWAS7
was used in the discovery phase, while data from the
GWAS performed by the Partners MS Center at the Brig-
ham and Women’s Hospital (BWH) and published as part
of a recent meta-analysis19 was used in the target phase.
In both of these GWAS, MS was diagnosed according to
standardized clinical criteria20 and stringent quality
control (QC) measures were applied to the data prior to
analysis (see original publications for details7,19).
The IMSGC GWAS7 was based on the Affymetrix Gene-
Chip Human Mapping 500K Array Set and consisted of
reliable data from 334,923 SNPs in 931 affected individuals
and 2,431 controls: 1,475 from the Wellcome Trust Case622 The American Journal of Human Genetics 86, 621–625, April 9, 2Control Consortium (randomly selected from the 1958
British Birth Cohort and the UK National Blood Transfu-
sion Service) and 956 from the National Institute of Mental
Health. Of the 931 cases, 453 were ascertained from sites
across the UK, and 478 were ascertained from the Partners
Healthcare MS Center in Boston and the UCSF MS Center.
The BWH GWAS19 was based on the Affymetrix Genome-
wide Human SNP Array 6.0 (GeneChip 6.0) which, after
excluding 54 individuals included in both GWAS, provided
reliable data from 713,683 SNPs in 806 affected individuals
ascertained from the Partners Healthcare MS Center in
Boston and 1,720 controls ascertained by the MIGen
consortium21 (394 from Spain, 63 from Sweden, 12 from
Finland, 746 from Seattle) and an additional 357 controls
ascertained in Boston.
To avoid the issue of scoring hemizygous individuals, we
based our analysis solely on autosomal SNPs and excluded
X and Y linked variants. SNPs with minor allele frequency
<0.05 were also excluded because in the sample sizes
available to us these SNPs have little or no power. To avoid
confounding inﬂuences from established MS susceptibility
variants (Table 1), we excluded these along with all SNPs
within 1 Mb of each established risk variant. Because of
the more extensive LD in the MHC region and greater
inﬂuence of this region, exclusion was extended to the
entire MHC (chromosome 6, 29700KB–33300KB). After
applying these exclusions, we were left with 311,315
SNPs with high-quality genotypes common to both
studies. By using the genotypes from both discovery and
target sets, we further pruned this consensus SNP panel
with the PLINK software suite to remove SNPs in strong
linkage disequilibrium with each other and thereby
generate a set of 59,470 essentially independent SNPs.
We used an r2 threshold of 0.2 within a 500 SNP window,
sliding 5 SNPs at a time.
We applied established methods for computing indi-
vidual risk score proﬁles22,23 to assess the polygenic effect
of multiple sclerosis. With the PLINK software suite, Co-
chran-Mantel-Haenszel test statistics were computed for
all SNPs in the discovery set, stratifying by geographic
origin (UK versus US samples). Based on these CMH associ-
ation tests, overlapping sets of scoring SNPs were generated
based on test signiﬁcance threshold (pT): pT < 0.01,
pT < 0.05, and pT deciles between 0.1 and 1 (Table 2).
By using the odds ratio point estimates from the
discovery set, we calculated an aggregate score for each
individual in the target set equal to the number of score
alleles weighted by the log of the odds ratio. Missing geno-
types in target individuals were given the mean score for
that locus as seen across the individuals not missing a
genotype at that locus. All score proﬁles were calculated
via PLINK’s score function.
To allow correction for any residual signal attributable to
established risk alleles that had not been removed by our
regional exclusion of SNPs ﬂanking established risk alleles,
we generated a score proﬁle based on the known suscepti-
bility variants listed in Table 1 (with rs3135388 as the010
Table 2. Target GWAS Statistics for Each Scoring SNP Set
p Value
Threshold Range
Number
of SNPs p Value
Nagelkerke’s
Pseudo-R2
0-0.01 746 3.14E-09 0.0126
0-0.05 3,272 1.39E-16 0.0243
0-0.1 6,426 2.45E-18 0.0271
0-0.2 12,627 2.62E-19 0.0287
0-0.3 18,564 7.53E-19 0.0279
0-0.4 24,565 1.29E-19 0.0292
0-0.5 30,365 8.93E-20 0.0294
0-0.6 36,160 3.35E-20 0.0301
0-0.7 42,075 1.22E-20 0.0308
0-0.8 48,012 1.73E-20 0.0305
0-0.9 53,748 1.05E-20 0.0309
0-1 59,470 6.12E-21 0.0313
The number of scoring SNPs falling into each p value threshold defined set is
shown (note these numbers are of course overlapping). Both the p value and
the pseudo-R2 are reported as a difference between a full model containing
score and covariates and a reduced model containing covariates only, evalu-
ated by likelihood ratio test.
Figure 1. Nagelkerke’s Pseudo-R2 for Each Scoring SNP Set
Variance explained in the target set, measured by Nagelkerke’s
pseudo-R2, is shown for each of the seven scoring SNP sets as
deﬁned by arbitrary discovery GWAS p value thresholds.surrogate for the MHC effect). Where susceptibility SNPs
were not typed in the target set, we selected proxies with
the highest r2 to the susceptibility SNP, with ties broken
by lowest physical distance (Table S1 available online).
With the aggregate scores generated in the target set, we
conducted logistic regression analysis to test the relation-
ship between the computed scores and disease status.
The score based on known-susceptibility variants and the
total number of nonmissing alleles over all SNPs were
included as covariates in the analysis. Logistic regression
analysis was conducted with STATA 10.1. The variance in
case/control status explained by the score statistic was esti-
mated as the difference in variance (with the Nagelkerke
pseudo-R2) between a model including score and the
covariates (full model) versus the covariates alone (reduced
model). p values were computed as 1-df likelihood ratio
tests between the full and reduced models.
To test for polygenic inﬂuences in multiple sclerosis, we
considered data from two MS GWAS7,19 and explored how
the risk of MS was related to the effects of multiple loci
considered collectively (‘‘en masse’’).18 After excluding
SNPs in LD with known MS susceptibility variants (see
Table 1) and ﬁltering SNPs on the basis of quality control
measures, allele frequency, and mutual LD, we established
a set of 59,470 essentially independent autosomal SNPs
common to both MS GWAS. These scoring SNPs were
then considered in seven sets deﬁned on the basis of
nominal signiﬁcance thresholds observed in the ﬁrst
GWAS7 (Table 2 indicates the number of scoring SNPs in
each signiﬁcance threshold deﬁned set). The ﬁrst GWAS7
(the discovery data set) was used to establish a score for
each allele at each of the 59,470 SNPs. Although theseThe Amodds ratio point estimates have wide conﬁdence intervals,
they are inevitably correlated with the true risk for the
assessed alleles. In the target data set (the second MS
GWAS19), we then calculated the aggregate score for each
sample by summing the number of risk alleles present in
the individual weighted by the score for that allele as calcu-
lated in the discovery set. These aggregate scores were then
subject to logistic regression analysis to determine whether
they account for signiﬁcant variance in disease status
within the target data set. This process was repeated for
each of the sets of scoring SNPs.
Each of the scoring SNP sets showed highly signiﬁcant
evidence for association to disease status (p ¼ 3.14E-
9–p ¼ 6.12E-21), conﬁrming that polygenic inheritance
determined by as-yet-unidentiﬁed genetic variation is
relevant in multiple sclerosis (see Figure 1 and Table 2).
Our analysis provides highly signiﬁcant evidence for a
polygenic component to the genetics of MS. As with other
complex diseases, it is becoming increasingly clear that
single genes explaining a large proportion of heritability
do not exist.24 The results of this study indicate that MS
risk is governed in part by the cumulative effect of multiple
genetic variants scattered across the genome, each contrib-
uting only a modest individual effect.
In contrast to the results of the schizophrenia study, the
variance explained in MS (as measured by the Nagelkerke’s
pseudo-R2 value) tended to stabilize once the SNP inclusion
cut-off reached an initial p value of 0.2. On the surface, this
might suggest that SNPs with somewhat larger effects (e.g.,
odds ratios of 1.1–1.3) are more prevalent in MS than in
schizophrenia. However, the fact that the level of pseudo-
R2 does not fall in scoring sets based on less signiﬁcant
thresholds suggests that this ﬂattening may be due to
limited power more than an absence of genuinely associ-
ated variants among those SNPs with p values of 0.2–0.5.
Some portion of the identiﬁed polygenic effect could be
due to cryptic population stratiﬁcation remaining in the
samples of European descent. However, common methodserican Journal of Human Genetics 86, 621–625, April 9, 2010 623
for correcting for such stratiﬁcation rely on the assumption
that there is no widely dispersed genomic effect on
the trait. This is exactly what we are testing, so applying
such correction will probably eliminate a true polygenic
effect. As pointed out in the original paper from the
ISC,18 en masse effects like those we have demonstrated
are unlikely to result from stratiﬁcation because the same
structure would need to be present in both data sets to
produce correlation between studies, a highly unlikely
scenario.
Although this analysis provides convincing evidence for
the existence of a polygenic inﬂuence on susceptibility, it
provides little if any guidance as to the location of the
relevant variants. Mapping these additional effects can be
achieved only through larger GWAS. Most of the common
variants with odds ratio> 1.2 should emerge from a GWAS
involving ~10,000 cases and ~10,000 controls, but even
larger studies will be required to map weaker effects.Supplemental Data
Supplemental Data include one table and can be found with this
article online at http://www.cell.com/AJHG.Acknowledgments
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